Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

April 3, 2019April 3, 2019

SB-525 Continues to Show Encouraging Results for Hemophilia A in Phase 1/2 Trial

News

Investigational gene therapy SB-525 is well-tolerated and leads to a dose-dependent increase in factor VIII (FVIII), according to interim results from eight patients with severe hemophilia A enrolled in the Phase 1/2 Alta ... Read more

March 20, 2019March 20, 2019

New Biomarker May Help Predict Response to Preventive Treatment with Factor VIII, Study Shows

News

New evidence suggests that a parameter called FVIII-EC50 has potential as a new way to predict the response of an individual with severe hemophilia to preventive treatment with FVIII, ... Read more

March 4, 2019March 4, 2019

Hemophilia A Patients Report Benefits of Using FuseNGo Device, Study Shows

News

According to hemophilia A patients, FuseNGo, Pfizer‘s pre-filled syringe device used for both the treatment and prevention of bleeding, is easy to use and has a wide range of ... Read more

February 27, 2019February 27, 2019

Discovery of Hemophilia A Subgroups May Help Predict FVIII Inhibitor Development

News

Researchers have identified four distinct subgroups of hemophilia A patients according to their profile of factor VIII-targeting antibodies. This may help predict those at risk for developing inhibitors that ... Read more

February 18, 2019February 18, 2019

Hemlibra Now Available to Patients in Developing Countries via Aid Program

News

Hemlibra (emicizumab), the sole approved prophylactic treatment for hemophilia A, is now available to patients in developing countries via the World Federation of Hemophilia (WFH) Humanitarian Aid Program after Roche and its ... Read more

December 21, 2018December 21, 2018

Hemophilia Patients Show Worse Oral Hygiene than Healthy Controls, Study Reports

News

Oral hygiene among children and adults with severe hemophilia is poorer than in healthy controls, a single-center study suggests. The study, “Oral hygiene and dentition status in children and ... Read more

December 10, 2018December 10, 2018

New Analysis Confirms Hemlibra’s Sustained Efficacy in Controlling Bleeding in Some Children With Hemophilia A

News

A new analysis of the Phase 3 HAVEN 2 study’s results shows that Genentech’s Hemlibra (emicizumab-kxwh) prophylaxis (preventive treatment) leads to significant reductions in the number of bleeds among hemophilia A children younger ... Read more

August 31, 2018August 31, 2018

FDA Approves Bayer’s Jivi for Hemophilia A Patients 12 and Older

News

The U.S. Food and Drug Administration has approved Bayer’s Jivi, previously known as BAY94-9027, as a preventive therapy for hemophilia A in patients ages 12 and older, the company announced. The ... Read more

June 27, 2018June 27, 2018

CB 2679d Brings Clotting Protein Levels Closer to Normal in Hemophilia B Patients, Phase 1/2 Data Show

News

Treatment with CB 2679d increased factor IX activity levels in the blood, bringing them closer to normal levels in the newest group of patients with severe hemophilia B in the Phase 1/2 ... Read more

June 15, 2018June 15, 2018

Data Supports Potential for Personalized Hemophilia A Therapy with Nuwiq, WFH Presentations Show

News

Since every hemophilia A patient responds differently to therapies, researchers are working to develop personalized preventive (prophylaxis) strategies with Nuwiq (antihemophilic factor .) Octapharma, the treatment’s manufacturer, presented data showing that ... Read more

Pin It on Pinterest